Page 6 - கனடியன் காப்புரிமை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from கனடியன் காப்புரிமை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In கனடியன் காப்புரிமை Today - Breaking & Trending Today

The New Rules Of Canadian Patent Litigation: Federal Court Of Appeal Affirms The Viability Of Summary Judgments In Patent Actions, Upholds Interpretation Of File Wrapper Estoppel - Intellectual Property

On January 20, 2021, the Federal Court of Appeal dismissed the
appeal in
CanMar Foods Ltd. v. TA Foods Ltd 2021 FCA 7.
This precedent setting appeal stems from the underlying decision of
Justice Manson which itself was recognized as the Canadian Patent
Impact Case of the Year by Managing Intellectual Property (MIP)
Americas Awards 2020. Gowling WLG successfully represented TA
Foods both at trial and on appeal. Our earlier articles and
discussion on the trial decision are available here and here.
This appellate decision reiterates that summary judgment is a
viable, efficient and relatively inexpensive procedural route to
exit patent actions even before discovery where it is clear that ....

United States , United Kingdom , Justice Manson , Patrick Smith , Property Institute , Canmar Foods Ltd , Ta Foods Ltd , Federal Court , Canmar Foods , Canadian Patent , Impact Case , Managing Intellectual Property , Americas Awards , Patent Act , Intellectual Property Institute , Justice De Montigny , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , நீதி மேன்சன் , பேட்ரிக் ஸ்மித் , ப்ராபர்டீ நிறுவனம் , தா உணவுகள் லிமிடெட் , கூட்டாட்சியின் நீதிமன்றம் , கனடியன் காப்புரிமை , தாக்கம் வழக்கு , நிர்வகித்தல் அறிவுசார் ப்ராபர்டீ ,

Federal Court Invalidates Janssen ZYTIGA® Patent - Intellectual Property

On January 14, 2021, the Federal Court issued a decision
(
Janssen Inc. et al v. Apotex Inc. et al, 2021 FC 7) in
the consolidated infringement action brought under s. 6(1) of the
Patented Medicine (Notice of Compliance) (PM(NOC))
Regulations by Janssen against Apotex, Dr. Reddy s
Laboratory, and Pharmascience. In this decision, the Court
invalidated the asserted claims of Janssen s Canadian Patent
2,661,422 (the 422 Patent), which claimed the combined use of the
two active ingredients found in Janssen s brand name drug
ZYTIGA, abiraterone acetate and prednisone, in the treatment of
prostate cancer. Concurrently, the Court dealt with Apotex
counterclaim under s. 6(3) of the
PM(NOC) Regulations to ....

Taro Pharmaceuticals Inc , Sunovion Pharmaceuticals , Janssen Inc , Free World , Canadian Patent Office , Canada Inc , Sanofi Synthelabo Canada Inc , Apotex Inc , Federal Court , Patented Medicine , Canadian Patent , Free World Trust , Asserted Claims , Patent Examination Notice , Federal Court Invalidates Janssen Zytiga Xae Patent , Intellectual Property , டாரோ மருந்துகள் இன்க் , ஜான்சன் இன்க் , இலவசம் உலகம் , கனடியன் காப்புரிமை அலுவலகம் , கனடா இன்க் , கூட்டாட்சியின் நீதிமன்றம் , காப்புரிமை பெற்றது மருந்து , கனடியன் காப்புரிமை , இலவசம் உலகம் நம்பிக்கை , காப்புரிமை தேர்வு அறிவிப்பு ,

Federal Court decision regarding glatiramer acetate finds one patent obvious and another valid and infringed | Smart & Biggar

To embed, copy and paste the code into your website or blog:
On January 6, 2021, the Federal Court issued its decision in two patent infringement actions pursuant to subsection 6(1) of the
Patented Medicines (Notice of Compliance) Regulations involving Teva’s patents pertaining to the drug
glatiramer acetate (Teva’s
GLATECT):
Teva v Pharmascience,2020 FC 1158. Justice Kane found Canadian Patent No. 2,702,437 (437 patent) invalid for obviousness while Canadian Patent No. 2,760,802 (802 patent) was found valid and infringed by Pharmascience if it proceeds to market its product.
COPAXONE 20 mg has been on the market since the mid-1990s for use in treating patients with relapsing-remitting multiple sclerosis (RRMS) and, in 2017, Pharmascience received a notice of compliance for GLATECT 20 mg for daily administration for this indication. COPAXONE 40 mg was approved in 2016 to be administered three times per week to treat patients with RRMS. Pharmascience ....

Tevav Pharmascience , Justice Kane , Federal Court , Patented Medicines , Canadian Patent , நீதி கேன் , கூட்டாட்சியின் நீதிமன்றம் , காப்புரிமை பெற்றது மருந்துகள் , கனடியன் காப்புரிமை ,

Federal Court continues recent trend of granting summary judgment in appropriate patent proceedings | Smart & Biggar

In a recent decision,
Flatwork Technologies LLC v Brierley (2020 FC 997), the Federal Court granted summary judgment in favour of the Plaintiff, Flatwork Technologies, LLC (
Flatwork), in respect of its patent impeachment action.
A motion for summary judgment is a streamlined and expeditious procedure whereby a party seeks to have the Court adjudicate some or all of the issues in an action based entirely on a paper record. Unlike a full trial which requires the parties to put forward live witnesses, in a motion for summary judgment all of the evidence is submitted by way of affidavits followed by cross-examinations on those affidavits. A motion for summary judgment may be brought at any time after the defendant has filed a defence but before the time and place for trial have been fixed. ....

Hryniakv Mauldin , Laura Easton , Matthew Norton , Daniel Davies , Supreme Court , Gilead Sciences Canada Inc , Flatwork Technologies , Canmar Foods Ltd , Gemakv Jempak Corporation , Court File No , Viiv Healthcare Company , Federal Court , Canadian Patent , Canmar Foods , Jempak Corporation , Gilead Sciences Canada , Court File , லாரா ஈஸ்டன் , மேத்யூ நார்டன் , டேனியல் டேவிஸ் , உச்ச நீதிமன்றம் , கிலியட் அறிவியல் கனடா இன்க் , தட்டையான வேலை தொழில்நுட்பங்கள் , நீதிமன்றம் கோப்பு இல்லை , கூட்டாட்சியின் நீதிமன்றம் , கனடியன் காப்புரிமை ,